KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease

키워드

참고문헌 (654)

1. Rockey DC, "Liver biopsy", Hepatology, 49, pp.1017~1044 (2009)
2. Poynard T, "Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C", Clin Chem, 50, pp.1344~1355 (2004)
3. Rosenberg WM, "Serum markers detect the presence of liver fibrosis : a cohort study", Gastroenterology, 127, pp.1704~1713 (2004)
4. Anstee QM, "Impact of non-invasive biomarkers on hepatology practice : past, present and future", J Hepatol, 76, pp.1362~1378 (2022)
5. Lee Y, "Diagnostic efficacy of serum asialo α1-acid glycoprotein levels for advanced liver fibrosis and cirrhosis in patients with chronic hepatitis B compared to that in healthy subjects : a prospective study", J Clin Med, 12, pp.712~ (2023)
6. Lee EY, "Development of a rapid, immunochromatographic strip test for serum asialo alpha1-acid glycoprotein in patients with hepatic disease", J Immunol Methods, 308, pp.116~123 (2006)
7. Sheth SG, "AST", ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection, 1998, pp.93, 44~48
8. Williams AL, "Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis", Gastroenterology, 95, pp.734~739 (1988)
9. Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
10. Harrison SA, "Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease", Gut, 57, pp.1441~1447 (2008)
11. Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
12. Angulo P, "The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD", Hepatology, 45, pp.846~854 (2007)
13. Forns X, "Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model", Hepatology, 36(4 Pt 1), pp.986~992 (2002)
14. McPherson S, "Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease", Gut, 59, pp.1265~1269 (2010)
15. Imperiale TF, "Need for validation of clinical decision aids : use of the AST", ALT ratio in predicting cirrhosis in chronic hepatitis C, 2000, pp.95, 2328~2332
16. Borsoi Viana MS, "Use of AST platelet ratio index(APRI score)as an alternative to liver biopsy for treatment indication in chronic hepatitis C", Ann Hepatol, 8, pp.26~31 (2009)
17. Calès P, "Comparison of blood tests for liver fibrosis specific or not to NAFLD", J Hepatol, 50, pp.165~173 (2009)
18. Loaeza-del-Castillo A, "AST to platelet ratio index(APRI)for the noninvasive evaluation of liver fibrosis", Ann Hepatol, 7, pp.350~357 (2008)
19. Anstee QM, "Noninvasive tests accurately identify advanced fibrosis due to NASH : baseline data from the STELLAR trials", Hepatology, 70, pp.1521~1530 (2019)
20. Jung J, "MRE combined with FIB-4(MEFIB)index in detection of candidates for pharmacological treatment of NASH-related fibrosis", Gut, 70, pp.1946~1953 (2021)
21. Boursier J, "Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events", J Hepatol, 76, pp.1013~1020 (2022)
22. Qureshi K, "The utility of the"NAFLD fibrosis score"in morbidly obese subjects with NAFLD", Obes Surg, 18, pp.264~270 (2008)
23. Wong VW, "Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis", Am J Gastroenterol, 103, pp.1682~1688 (2008)
24. Harrison SA, "A blood-based biomarker panel(NIS4)for noninvasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis : a prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.970~985 (2020)
25. Narimatsu H, "Development of M2BPGi : a novel fibrosis serum glyco-biomarker for chronic hepatitis", cirrhosis diagnostics, 2015, pp.12, 683~693
26. Shirabe K, "Mac-2 binding protein glycan isomer(M2BPGi)is a new serum biomarker for assessing liver fibrosis : more than a biomarker of liver fibrosis", J Gastroenterol, 53, pp.819~826 (2018)
27. Daniels SJ, "ADAPT : an algorithm incorporating PROC3accurately identifies patients with NAFLD and advanced fibrosis", Hepatology, 69, pp.1075~1086 (2019)
28. Boyle M, "Performance of the PRO-C3 collagen neoepitope biomarker in non-alcoholic fatty liver disease", JHEP Rep, 1, pp.188~198 (2019)
29. Guha IN, "Noninvasive markers of fibrosis in nonalcoholic fatty liver disease : validating the European liver fibrosis panel and exploring simple markers", Hepatology, 47, pp.455~460 (2008)
30. Ratziu V, "Diagnostic value of biochemical markers(FibroTest-FibroSURE)for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease", BMC Gastroenterol, 6, pp.6~ (2006)
31. Harrison SA, "NIS2+TM, an optimisation of the blood-based biomarker NIS4® technology for the detection of atrisk NASH : a prospective derivation and validation study", J Hepatol, 79, pp.758~767 (2023)
32. Munteanu M, "Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference", Aliment Pharmacol Ther, 44, pp.877~889 (2016)
33. Sharma S, "Non-invasive diagnosis of advanced fibrosis and cirrhosis", World J Gastroenterol, 20, pp.16820~16830 (2014)
34. Tatler AL, "Recent advances in the non-invasive assessment of fibrosis using biomarkers", Curr Opin Pharmacol, 49, pp.110~115 (2019)
35. McPherson S, "Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis", Am J Gastroenterol, 112, pp.740~751 (2017)
36. Horowitz JM, "Evaluation of hepatic fibrosis : a review from the society of abdominal radiology disease focus panel", Abdom Radiol(NY), 42, pp.2037~2053 (2017)
37. Tang A, "Ultrasound elastography and MR elastography for assessing liver fibrosis : part 1, principles and techniques", AJR Am J Roentgenol, 205, pp.22~32 (2015)
38. Barr RG, "Elastography assessment of liver fibrosis : Society of Radiologists in Ultrasound consensus conference statement", Radiology, 276, pp.845~861 (2015)
39. Sandrin L, "Transient elastography : a new noninvasive method for assessment of hepatic fibrosis", Ultrasound Med Biol, 29, pp.1705~1713 (2003)
40. Shiina T, "WFUMB guidelines and recommendations for clinical use of ultrasound elastography : part 1 : basic principles and terminology", Ultrasound Med Biol, 41, pp.1126~1147 (2015)
41. Oliveri F, "Liver stiffness in the hepatitis B virus carrier : a non-invasive marker of liver disease influenced by the pattern of transaminases", World J Gastroenterol, 14, pp.6154~6162 (2008)
42. Myers RP, "Controlled Attenuation Parameter(CAP) : a noninvasive method for the detection of hepatic steatosis based on transient elastography", Liver Int, 32, pp.902~910 (2012)
43. Choi BI, "Ultrasound elastography for liver disease with focus on hepatic fibrosis", Clin Ultrasound, 7, pp.1~10 (2022)
44. Mederacke I, "Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection", Liver Int, 29, pp.1500~1506 (2009)
45. Kim SU, "Variability in liver stiffness values from different intercostal spaces", Liver Int, 29, pp.760~766 (2009)
46. Boursier J, "Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography", Eur J Gastroenterol Hepatol, 20, pp.693~701 (2008)
47. Marcellin P, "Noninvasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B", Liver Int, 29, pp.242~247 (2009)
48. Kim DY, "Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B", Dig Dis Sci, 54, pp.1758~1763 (2009)
49. Chan HL, "Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography(Fibroscan)for liver fibrosis in chronic hepatitis B", J Viral Hepat, 16, pp.36~44 (2009)
50. Kim SU, "Transient elastography in chronic hepatitis B : an Asian perspective", World J Gastroenterol, 16, pp.5173~5180 (2010)
51. Lucidarme D, "Factors of accuracy of transient elastography(fibroscan)for the diagnosis of liver fibrosis in chronic hepatitis C", Hepatology, 49, pp.1083~1089 (2009)
52. Myers RP, "Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy", Liver Int, 30, pp.1471~1480 (2010)
53. Sagir A, "Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage", Hepatology, 47, pp.592~595 (2008)
54. Arena U, "Acute viral hepatitis increases liver stiffness values measured by transient elastography", Hepatology, 47, pp.380~384 (2008)
55. Coco B, "Transient elastography : a new surrogate marker of liver fibrosis influenced by major changes of transaminases", J Viral Hepat, 14, pp.360~369 (2007)
56. Kim SU, "How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B?", J Clin Gastroenterol, 44, pp.66~71 (2010)
57. Millonig G, "Extrahepatic cholestasis increases liver stiffness(FibroScan)irrespective of fibrosis", Hepatology, 48, pp.1718~1723 (2008)
58. Millonig G, "Liver stiffness is directly influenced by central venous pressure", J Hepatol, 52, pp.206~210 (2010)
59. Bardou-Jacquet E, "Effect of alcohol consumption on liver stiffness measured by transient elastography", World J Gastroenterol, 19, pp.516~522 (2013)
60. Mueller S, "Increased liver stiffness in alcoholic liver disease : differentiating fibrosis from steatohepatitis", World J Gastroenterol, 16, pp.966~972 (2010)
61. Trabut JB, "Rapid decline of liver stiffness following alcohol withdrawal in heavy drinkers", Alcohol Clin Exp Res, 36, pp.1407~1411 (2012)
62. Bercoff J, "Supersonic shear imaging : a new technique for soft tissue elasticity mapping", IEEE Trans Ultrason Ferroelectr Freq Control, 51, pp.396~409 (2004)
63. Bamber J, "EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1 : basic principles and technology", Ultraschall Med, 34, pp.169~184 (2013)
64. Sarvazyan AP, "Shear wave elasticity imaging : a new ultrasonic technology of medical diagnostics", Ultrasound Med Biol, 24, pp.1419~1435 (1998)
65. Jeong WK, "Principles and clinical application of ultrasound elastography for diffuse liver disease", Ultrasonography, 33, pp.149~160 (2014)
66. Ozturk A, "Principles of ultrasound elastography", Abdom Radiol(NY), 43, pp.773~785 (2018)
67. Sigrist RMS, "Ultrasound elastography : review of techniques and clinical applications", Theranostics, 7, pp.1303~1329 (2017)
68. Ferraioli G, "Liver Ultrasound elastography : an update to the World Federation for Ultrasound in Medicine and Biology guidelines and recommendations", Ultrasound Med Biol, 44, pp.2419~2440 (2018)
69. Barr RG, "Update to the Society of Radiologists in Ultrasound Liver Elastography consensus statement", Radiology, 296, pp.263~274 (2020)
70. Barr RG, "Shear wave liver elastography", Abdom Radiol(NY), 43, pp.800~807 (2018)
71. Cassinotto C, "Liver stiffness in nonalcoholic fatty liver disease : a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy", Hepatology, 63, pp.1817~1827 (2016)
72. Zhou X, "Comparison of 2-D shear wave elastography and point shear wave elastography for assessing liver fibrosis", Ultrasound Med Biol, 47, pp.408~427 (2021)
73. Tang A, "Ultrasound elastography and MR elastography for assessing liver fibrosis : part 2, diagnostic performance, confounders, and future directions", AJR Am J Roentgenol, 205, pp.33~40 (2015)
74. Woo H, "Comparison of the reliability of acoustic radiation force impulse imaging and supersonic shear imaging in measurement of liver stiffness", Radiology, 277, pp.881~886 (2015)
75. Lee ES, "Shear wave liver elastography with a propagation map : diagnostic performance and inter-observer correlation for hepatic fibrosis in chronic hepatitis", Ultrasound Med Biol, 43, pp.1355~1363 (2017)
76. Agrò FE, "Body fluid management : from physiology to therapy" (2013), Springer
77. Pinsky MR, "Functional hemodynamic monitoring" (2005), Springer
78. Kennedy P, "Quantitative elastography methods in liver disease : current evidence and future directions", Radiology, 286, pp.738~763 (2018)
79. Fang C, "Reducing the number of measurements in liver point shear-wave elastography : factors that influence the number and reliability of measurements in assessment of liver fibrosis in clinical practice", Radiology, 287, pp.844~852 (2018)
80. Ferraioli G, "Accuracy of the ElastPQ technique for the assessment of liver fibrosis in patients with chronic hepatitis C : a"real life"single center study", J Gastrointestin Liver Dis, 25, pp.331~335 (2016)
81. European Association for the Study of the Liver, "EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update", J Hepatol, 75, pp.659~689 (2021)
82. Dzyubak B, "Automated liver elasticity calculation for MR elastography", J Magn Reson Imaging, 43, pp.1055~1063 (2016)
83. Gandhi DB, "Assessment of agreement between manual and automated processing of liver MR elastography for shear stiffness estimation in children and young adults with autoimmune liver disease", Abdom Radiol(NY), 46, pp.3927~3934 (2021)
84. Zhang YN, "Liver fibrosis imaging : a clinical review of ultrasound and magnetic resonance elastography", J Magn Reson Imaging, 51, pp.25~42 (2020)
85. "QIBA Profile: Magnetic Resonance Elastography of the Liver"[URL]
86. Trout AT, "Liver stiffness measurements with MR elastography : agreement and repeatability across imaging systems, field strengths, and pulse sequences", Radiology, 281, pp.793~804 (2016)
87. Kim HJ, "Reproducibility of hepatic MR elastography across field strengths, pulse sequences, scan intervals, and readers", Abdom Radiol(NY), 45, pp.107~115 (2020)
88. Yin M, "Hepatic MR elastography : clinical performance in a series of 1377 consecutive examinations", Radiology, 278, pp.114~124 (2016)
89. Abe K, "Utility of magnetic resonance elastography for predicting ascites in patients with chronic liver disease", J Gastroenterol Hepatol, 33, pp.733~740 (2018)
90. Asbach P, "Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography", Radiology, 257, pp.80~86 (2010)
91. Shi Y, "MR elastography for the assessment of hepatic fibrosis in patients with chronic hepatitis B infection : does histologic necroinflammation influence the measurement of hepatic stiffness?", Radiology, 273, pp.88~98 (2014)
92. Ichikawa S, "Hepatitis activity should be considered a confounder of liver stiffness measured with MR elastography", J Magn Reson Imaging, 41, pp.1203~1208 (2015)
93. Kim DK, "Clinical feasibility of MR elastography in patients with biliary obstruction", AJR Am J Roentgenol, 210, pp.1273~1278 (2018)
94. Chen J, "Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis", Eur Radiol, 32, pp.950~958 (2022)
95. Leitão HS, "Hepatic fibrosis, inflammation, and steatosis : influence on the MR viscoelastic and diffusion parameters in patients with chronic liver disease", Radiology, 283, pp.98~107 (2017)
96. Shi Y, "Threedimensional MR elastography depicts liver inflammation, fibrosis, and portal hypertension in chronic hepatitis B or C", Radiology, 301, pp.154~162 (2021)
97. Yin M, "Distinguishing between hepatic inflammation and fibrosis with MR elastography", Radiology, 284, pp.694~705 (2017)
98. Allen AM, "The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery", Hepatology, 71, pp.510~521 (2020)
99. Allen AM, "Multiparametric magnetic resonance elastography improves the detection of NASH regression following bariatric surgery", Hepatol Commun, 4, pp.185~192 (2020)
100. Korean Association for the Study of the Liver(KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clin Mol Hepatol, 28, pp.276~331 (2022)
101. Tang LSY, "Chronic hepatitis B infection : a review", JAMA, 319, pp.1802~1813 (2018)
102. Xiao G, "Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection : a systemic review and meta-analysis", Hepatology, 61, pp.292~302 (2015)
103. Sebastiani G, "The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of noninvasive fibrosis biomarkers : an international study of 2411 cases", Aliment Pharmacol Ther, 34, pp.1202~1216 (2011)
104. Zhu X, "Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy", AST platelet ratio index and FIB-4 in patients with chronic HBV infection, 2011, pp.56, 2742~2749
105. Jin W, "Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis : a leading meta-analysis", BMC Gastroenterol, 12, pp.14~ (2012)
106. Kim BK, "Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B", PLoS One, 7, pp.e35825~ (2012)
107. Salkic NN, "FibroTest", Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B : a meta-analysis, 2014, pp.109, 796~809
108. Degos F, "Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis : a multicenter prospective study(the FIBROSTIC study)", J Hepatol, 53, pp.1013~1021 (2010)
109. Houot M, "Systematic review with meta-analysis : direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B", Aliment Pharmacol Ther, 43, pp.16~29 (2016)
110. Kuno A, "A serum"sweet-doughnut"protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis", Sci Rep, 3, pp.1065~ (2013)
111. Nishikawa H, "Proposal of a predictive model for advanced fibrosis containing Wisteria floribunda agglutinin-positive Mac-2-binding protein in chronic hepatitis C", Hepatol Res, 47, pp.E74~E84 (2017)
112. Feng S, "Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis : an updated meta-analysis", Sci Rep, 10, pp.10582~ (2020)
113. Munteanu M, "Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors : FibroTest-FibroMax experience", J Gastrointestin Liver Dis, 17, pp.187~191 (2008)
114. Maimone S, "An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers", J Viral Hepat, 16, pp.769~774 (2009)
115. Castéra L, "Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers", Aliment Pharmacol Ther, 33, pp.455~465 (2011)
116. Sporea I, "Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis : a comparative study", World J Gastroenterol, 16, pp.4832~4837 (2010)
117. Viganò M, "Dual cutoff transient elastography to assess liver fibrosis in chronic hepatitis B : a cohort study with internal validation", Aliment Pharmacol Ther, 34, pp.353~362 (2011)
118. Verveer C, "Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C", Liver Int, 32, pp.622~628 (2012)
119. Cardoso AC, "Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C", Liver Int, 32, pp.612~621 (2012)
120. Chon YE, "Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B : a meta-analysis", PLoS One, 7, pp.e44930~ (2012)
121. Li Y, "Systematic review with meta-analysis : the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B", Aliment Pharmacol Ther, 43, pp.458~469 (2016)
122. Qi X, "Transient elastography for significant liver fibrosis and cirrhosis in chronic hepatitis B : a meta-analysis", Can J Gastroenterol Hepatol, 2018, pp.3406789~ (2018)
123. Mingkai L, "Diagnostic performance of elastography on liver fibrosis in antiviral treatment-naive chronic hepatitis B patients: a meta-analysis", Gastroenterol Rep (Oxf), 10, pp.goac005~ (2022)
124. Xu X, "Performance of transient elastography assessing fibrosis of single hepatitis B virus infection : a systematic review and meta-analysis of a diagnostic test", Hepatol Int, 9, pp.558~566 (2015)
125. Boursier J, "The combination of a blood test and fibroscan improves the non-invasive diagnosis of liver fibrosis", Liver Int, 29, pp.1507~1515 (2009)
126. Heo JY, "Combination of transient elastography and an enhanced liver fibrosis test to assess the degree of liver fibrosis in patients with chronic hepatitis B", Gut Liver, 12, pp.190~200 (2018)
127. Fraquelli M, "Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C", J Hepatol, 54, pp.621~628 (2011)
128. Friedrich-Rust M, "Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis : a pooled meta-analysis", J Viral Hepat, 19, pp.e212~e219 (2012)
129. Friedrich-Rust M, "Acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in chronic hepatitis B", J Viral Hepat, 20, pp.240~247 (2013)
130. Zhang D, "Comparison of acoustic radiation force impulse imaging and transient elastography for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B", Ultrasound Med Biol, 41, pp.7~14 (2015)
131. Dong DR, "Acoustic radiation force impulse elastography, FibroScan®, Forns’ index and their combination in the assessment of liver fibrosis in patients with chronic hepatitis B, and the impact of inflammatory activity and steatosis on these diagnostic methods", Mol Med Rep, 11, pp.4174~4182 (2015)
132. Park MS, "Factors influencing the diagnostic accuracy of acoustic radiation force impulse elastography in patients with chronic hepatitis B", Gut Liver, 10, pp.275~282 (2016)
133. Li J, "Acoustic Radiation Force Impulse(ARFI)elastography and serological markers in assessment of liver fibrosis and free portal pressure in patients with hepatitis B", Med Sci Monit, 23, pp.3585~3592 (2017)
134. Leung VY, "Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers : comparison of shearwave elastography and transient elastography with liver biopsy correlation", Radiology, 269, pp.910~918 (2013)
135. Zeng J, "Diagnostic accuracy of two-dimensional shear wave elastography for the non-invasive staging of hepatic fibrosis in chronic hepatitis B : a cohort study with internal validation", Eur Radiol, 24, pp.2572~2581 (2014)
136. Zheng J, "Two-dimensional shear-wave elastography and conventional US : the optimal evaluation of liver fibrosis and cirrhosis", Radiology, 275, pp.290~300 (2015)
137. Wu T, "Comparison of two-dimensional shear wave elastography and realtime tissue elastography for assessing liver fibrosis in chronic hepatitis B", Dig Dis, 34, pp.640~649 (2016)
138. Zhuang Y, "Twodimensional shear-wave elastography performance in the noninvasive evaluation of liver fibrosis in patients with chronic hepatitis B : comparison with serum fibrosis indexes", Radiology, 283, pp.873~882 (2017)
139. Zeng J, "Comparison of 2-D shear wave elastography and transient elastography for assessing liver fibrosis in chronic hepatitis B", Ultrasound Med Biol, 43, pp.1563~1570 (2017)
140. Xie X, "Liver stiffness as measured by two-dimensional shear wave elastography overestimates the stage of fibrosis in patients with chronic hepatitis B and hepatic steatosis", Clin Res Hepatol Gastroenterol, 45, pp.101421~ (2021)
141. Song L, "Staging liver fibrosis in patients with chronic hepatitis B using two-dimensional shear wave elastography based on histopathological findings : a prospective multicenter study", Quant Imaging Med Surg, 13, pp.2376~2387 (2023)
142. Wei H, "Two-dimensional shear wave elastography for significant liver fibrosis in patients with chronic hepatitis B : a systematic review and metaanalysis", Eur J Radiol, 124, pp.108839~ (2020)
143. Dong B, "Comparison of two-dimensional shear wave elastography, magnetic resonance elastography, and three serum markers for diagnosing fibrosis in patients with chronic hepatitis B : a metaanalysis", Expert Rev Gastroenterol Hepatol, 15, pp.1077~1089 (2021)
144. Herrmann E, "Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography : an individual patient data-based meta-analysis", Hepatology, 67, pp.260~272 (2018)
145. Karagiannakis DS, "Comparative utility of transient and 2D shear wave elastography for the assessment of liver fibrosis in clinical practice", J Digit Imaging, 34, pp.1342~1348 (2021)
146. Dietrich CF, "EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017(long version)", Ultraschall Med, 38, pp.377~394 (2017)
147. Zeng J, "Shear wave elastography for liver fibrosis in chronic hepatitis B : adapting the cut-offs to alanine aminotransferase levels improves accuracy", Eur Radiol, 29, pp.857~865 (2019)
148. Wang K, "Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B : a prospective multicentre study", Gut, 68, pp.729~741 (2019)
149. Lee JE, "Noninvasive assessment of hepatic fibrosis in patients with chronic hepatitis B viral infection using magnetic resonance elastography", Korean J Radiol, 15, pp.210~217 (2014)
150. Venkatesh SK, "Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B", Eur Radiol, 24, pp.70~78 (2014)
151. Chang W, "Liver fibrosis staging with MR elastography : comparison of diagnostic performance between patients with chronic hepatitis B and those with other etiologic causes", Radiology, 280, pp.88~97 (2016)
152. Park HS, "Assessing significant fibrosis using imaging-based elastography in chronic hepatitis B patients : pilot study", World J Gastroenterol, 25, pp.3256~3267 (2019)
153. Xiao H, "Comparison of diagnostic accuracy of magnetic resonance elastography and fibroscan for detecting liver fibrosis in chronic hepatitis B patients : a systematic review and meta-analysis", PLoS One, 12, pp.e0186660~ (2017)
154. Guo Y, "Magnetic resonance elastography and acoustic radiation force impulse for staging hepatic fibrosis : a metaanalysis", Abdom Imaging, 40, pp.818~834 (2015)
155. Castera L, "Non-invasive evaluation of liver fibrosis using transient elastography", J Hepatol, 48, pp.835~847 (2008)
156. Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
157. Vallet-Pichard A, "FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)
158. Martinez SM, "Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C", Aliment Pharmacol Ther, 33, pp.138~148 (2011)
159. Zarski JP, "Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C : the ANRS HCEP-23 study", J Hepatol, 56, pp.55~62 (2012)
160. Li J, "The validity of serum markers for fibrosis staging in chronic hepatitis B and C", J Viral Hepat, 21, pp.930~937 (2014)
161. Yen YH, "APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level", PLoS One, 13, pp.e0199760~ (2018)
162. Mada PK, "Predicting liver fibrosis in the hepatitis C population : concordance analysis between noninvasive scoring systems and percutaneous liver biopsy", Cureus, 12, pp.e10376~ (2020)
163. Paggi S, "A noninvasive algorithm accurately predicts advanced fibrosis in hepatitis C : a comparison using histology with internal-external validation", J Hepatol, 49, pp.564~571 (2008)
164. Lichtinghagen R, "The Enhanced Liver Fibrosis(ELF)score : normal values, influence factors and proposed cut-off values", J Hepatol, 59, pp.236~242 (2013)
165. Poynard T, "Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C : a step toward the truth in the absence of a gold standard", J Hepatol, 56, pp.541~548 (2012)
166. Imbert-Bismut F, "Biochemical markers of liver fibrosis in patients with hepatitis C virus infection : a prospective study", Lancet, 357, pp.1069~1075 (2001)
167. Joo SK, "Prospective comparison of noninvasive fibrosis assessment to predict advanced fibrosis or cirrhosis in Asian patients with hepatitis C", J Clin Gastroenterol, 49, pp.697~704 (2015)
168. Crossan C, "Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease : systematic review and economic evaluation", Health Technol Assess, 19, pp.1~409 (2015)
169. Lin ZH, "Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis : an updated meta-analysis", Hepatology, 53, pp.726~736 (2011)
170. Sharma C, "Systematic review : accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis", J Gastroenterol Hepatol, 36, pp.1788~1802 (2021)
171. Adams LA, "Hepascore : an accurate validated predictor of liver fibrosis in chronic hepatitis C infection", Clin Chem, 51, pp.1867~1873 (2005)
172. Calès P, "A novel panel of blood markers to assess the degree of liver fibrosis", Hepatology, 42, pp.1373~1381 (2005)
173. Leroy V, "Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C : comparison with PIIINP and hyaluronic acid", Am J Gastroenterol, 99, pp.271~279 (2004)
174. Sud A, "Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index", Hepatology, 39, pp.1239~1247 (2004)
175. Castéra L, "Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C", Gastroenterology, 128, pp.343~350 (2005)
176. Ziol M, "Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C", Hepatology, 41, pp.48~54 (2005)
177. Ganne-Carrié N, "Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases", Hepatology, 44, pp.1511~1517 (2006)
178. Castéra L, "Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C : comparison of transient elastography(FibroScan)with standard laboratory tests and non-invasive scores", J Hepatol, 50, pp.59~68 (2009)
179. Schwabl P, "New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension", Liver Int, 35, pp.381~390 (2015)
180. Seo YS, "Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis : a multicentre, retrospective study", Liver Int, 35, pp.2246~2255 (2015)
181. Singh S, "American Gastroenterological Association institute technical review on the role of elastography in chronic liver diseases", Gastroenterology, 152, pp.1544~1577 (2017)
182. Boursier J, "A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis", J Hepatol, 66, pp.1158~1165 (2017)
183. Calès P, "Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C : agreement or combination?", Aliment Pharmacol Ther, 45, pp.991~1003 (2017)
184. Broquetas T, "Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease", Liver Int, 41, pp.2733~2746 (2021)
185. Sporea I, "Acoustic radiation force impulse elastography for fibrosis evaluation in patients with chronic hepatitis C : an international multicenter study", Eur J Radiol, 81, pp.4112~4118 (2012)
186. Friedrich-Rust M, "Point shear wave elastography by acoustic radiation force impulse quantification in comparison to transient elastography for the noninvasive assessment of liver fibrosis in chronic hepatitis C : a prospective international multicenter study", Ultraschall Med, 36, pp.239~247 (2015)
187. Conti F, "Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C", Liver Int, 37, pp.187~195 (2017)
188. Abe T, "Accuracy of 2D shear wave elastography in the diagnosis of liver fibrosis in patients with chronic hepatitis C", J Clin Ultrasound, 46, pp.319~327 (2018)
189. Fouad R, "Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients", Eur J Gastroenterol Hepatol, 30, pp.882~887 (2018)
190. Ichikawa S, "Magnetic resonance elastography for staging liver fibrosis in chronic hepatitis C", Magn Reson Med Sci, 11, pp.291~297 (2012)
191. Numao H, "The utility of two-dimensional real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C virus infection", Eur J Gastroenterol Hepatol, 33, pp.1400~1407 (2021)
192. Singh S, "Diagnostic performance of magnetic resonance elastography in staging liver fibrosis : a systematic review and meta-analysis of individual participant data", Clin Gastroenterol Hepatol, 13, pp.440~451 (2015)
193. Lee HA, "Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease", Abdom Radiol(NY), 47, pp.3733~3745 (2022)
194. Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
195. Ryan CK, "One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation", Liver Transpl, 8, pp.1114~1122 (2002)
196. Wu J, "Prevalence of liver steatosis and fibrosis and the diagnostic accuracy of ultrasound in bariatric surgery patients", Obes Surg, 22, pp.240~247 (2012)
197. Saadeh S, "The utility of radiological imaging in nonalcoholic fatty liver disease", Gastroenterology, 123, pp.745~750 (2002)
198. Joo SK, "Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease", Liver Int, 38, pp.331~341 (2018)
199. Petta S, "Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease", Am J Gastroenterol, 114, pp.916~928 (2019)
200. Han S, "Accuracy of noninvasive scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease : a systematic review and meta-analysis", Gut Liver, 16, pp.952~963 (2022)
201. Gordon SC, "Health care use and costs among patients with nonalcoholic steatohepatitis with advanced fibrosis using the fibrosis-4 score", Hepatol Commun, 4, pp.998~1011 (2020)
202. Vali Y, "Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD : a systematic review and meta-analysis", J Hepatol, 73, pp.252~262 (2020)
203. Imajo K, "Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography", Gastroenterology, 150, pp.626~637 (2016)
204. Mózes FE, "Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis", Gut, 71, pp.1006~1019 (2022)
205. Musso G, "Meta-analysis : natural history of nonalcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity", Ann Med, 43, pp.617~649 (2011)
206. Ruffillo G, "Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease", J Hepatol, 54, pp.160~163 (2011)
207. Parker R, "Can clinical scoring systems replace liver biopsy in non-alcoholic fatty liver disease", J Hepatol, 51, pp.189~ (2009)
208. Wong VW, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease", Hepatology, 51, pp.454~462 (2010)
209. Sumida Y, "A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease", J Gastroenterol, 46, pp.257~268 (2011)
210. Pimentel SK, "Evaluation of the nonalcoholic fat liver disease fibrosis score for patients undergoing bariatric surgery", Arq Gastroenterol, 47, pp.170~173 (2010)
211. Jun DW, "External validation of the nonalcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients", J Gastroenterol Hepatol, 32, pp.1094~1099 (2017)
212. Chang D, "Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis", Hepatology, 77, pp.546~557 (2023)
213. Lee J, "Machine learning algorithm improves the detection of NASH(NAS-based)and at-risk NASH : a development and validation study", Hepatology, 78, pp.258~271 (2023)
214. Tamaki N, "Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease", Sci Rep, 9, pp.10109~ (2019)
215. Jekarl DW, "Diagnosis of liver fibrosis with Wisteria floribunda agglutininpositive Mac-2 binding protein(WFA-M2BP)among chronic hepatitis B patients", Ann Lab Med, 38, pp.348~354 (2018)
216. Heo JY, "Use of Wisteria floribunda agglutinin-positive human Mac-2binding protein in assessing risk of hepatocellular carcinoma due to hepatitis B virus", Medicine(Baltimore), 95, pp.e3328~ (2016)
217. Kim SU, "Diagnostic performance of serum asialo-α1-acid glycoprotein for advanced liver fibrosis or cirrhosis in patients with chronic hepatitis B or nonalcoholic fatty liver disease", Korean J Gastroenterol, 74, pp.341~348 (2019)
218. Koo BK, "Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease", Liver Int, 38, pp.695~705 (2018)
219. Corey KE, "ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD", J Hepatol, 76, pp.25~33 (2022)
220. Koo BK, "Development and validation of a scoring system, based on genetic and clinical factors, to determine risk of steatohepatitis in Asian patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 18, pp.2592~2599 (2020)
221. Xu K, "External validation of the nonalcoholic steatohepatitis scoring system in patients with biopsyproven nonalcoholic fatty liver disease in China", Clin Gastroenterol Hepatol, 19, pp.412~413 (2021)
222. Lee G, "Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD", Nat Commun, 11, pp.4982~ (2020)
223. Lupsor M, "Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis", J Gastrointestin Liver Dis, 19, pp.53~60 (2010)
224. Gaia S, "Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis", J Hepatol, 54, pp.64~71 (2011)
225. Petta S, "Reliability of liver stiffness measurement in non-alcoholic fatty liver disease : the effects of body mass index", Aliment Pharmacol Ther, 33, pp.1350~1360 (2011)
226. Kumar R, "Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease : diagnostic performance and clinicopathological correlation", Dig Dis Sci, 58, pp.265~274 (2013)
227. Mahadeva S, "Performance of transient elastography(TE)and factors associated with discordance in non-alcoholic fatty liver disease", J Dig Dis, 14, pp.604~610 (2013)
228. Naveau S, "The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD", Obes Surg, 24, pp.1693~1701 (2014)
229. Chan WK, "A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis", Hepatol Int, 9, pp.594~602 (2015)
230. Boursier J, "Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease", J Hepatol, 65, pp.570~578 (2016)
231. Rosso C, "Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis", Dig Liver Dis, 48, pp.55~61 (2016)
232. Lee MS, "Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease", PLoS One, 12, pp.e0188321~ (2017)
233. Park CC, "Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease", Gastroenterology, 152, pp.598~607 (2017)
234. Garg H, "Utility of transient elastography(fibroscan)and impact of bariatric surgery on nonalcoholic fatty liver disease(NAFLD)in morbidly obese patients", Surg Obes Relat Dis, 14, pp.81~91 (2018)
235. Furlan A, "Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease", AJR Am J Roentgenol, 214, pp.W20~W26 (2020)
236. Oeda S, "Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M", XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease : a multicenter prospective study, 2020, pp.55, 428~440
237. Lee DH, "A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 55, pp.994~1007 (2022)
238. Kwok R, "Systematic review with meta-analysis : non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments", Aliment Pharmacol Ther, 39, pp.254~269 (2014)
239. Castéra L, "Pitfalls of liver stiffness measurement : a 5-year prospective study of 13, 369 examinations", Hepatology, 51, pp.828~835 (2010)
240. Vuppalanchi R, "Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease", Hepatology, 67, pp.134~144 (2018)
241. Wong VW, "Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease", Am J Gastroenterol, 107, pp.1862~1871 (2012)
242. Wong VW, "Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease", Gut, 68, pp.2057~2064 (2019)
243. Petta S, "The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease", Hepatology, 62, pp.1101~1110 (2015)
244. Petta S, "Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values", Hepatology, 65, pp.1145~1155 (2017)
245. Chen J, "Diagnostic performance of MR elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity", Radiology, 283, pp.418~428 (2017)
246. Newsome PN, "FibroScan-AST(FAST)score for the noninvasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis : a prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.362~373 (2020)
247. Sanyal AJ, "Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores", J Hepatol, 78, pp.247~259 (2023)
248. Pennisi G, "Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease(NAFLD)and type 2 diabetes", Hepatology, 78, pp.195~211 (2023)
249. Karlas T, "Evaluation of transient elastography, acoustic radiation force impulse imaging(ARFI), and enhanced liver function(ELF)score for detection of fibrosis in morbidly obese patients", PLoS One, 10, pp.e0141649~ (2015)
250. Liu H, "Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients : a systematic review & meta-analysis", PLoS One, 10, pp.e0127782~ (2015)
251. Yoneda M, "Nonalcoholic fatty liver disease : US-based acoustic radiation force impulse elastography", Radiology, 256, pp.640~647 (2010)
252. Bota S, "Meta-analysis : ARFI elastography versus transient elastography for the evaluation of liver fibrosis", Liver Int, 33, pp.1138~1147 (2013)
253. Selvaraj EA, "Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD : a systematic review and meta-analysis", J Hepatol, 75, pp.770~785 (2021)
254. Imajo K, "Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 20, pp.908~917 (2022)
255. Chimoriya R, "The use of two-dimensional shear wave elastography in people with obesity for the assessment of liver fibrosis in non-alcoholic fatty liver disease", J Clin Med, 10, pp.95~ (2020)
256. Chen J, "Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography", Radiology, 259, pp.749~756 (2011)
257. Loomba R, "Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease : a prospective study", Hepatology, 60, pp.1920~1928 (2014)
258. Kim D, "Advanced fibrosis in nonalcoholic fatty liver disease : noninvasive assessment with MR elastography", Radiology, 268, pp.411~419 (2013)
259. Hsu C, "Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease : a systematic review and pooled analysis of individual participants", Clin Gastroenterol Hepatol, 17, pp.630~637 (2019)
260. Singh S, "Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease : a diagnostic accuracy systematic review and individual participant data pooled analysis", Eur Radiol, 26, pp.1431~1440 (2016)
261. Ajmera V, "Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease : a systematic review and meta-analysis of individual participants", Gastroenterology, 163, pp.1079~1089 (2022)
262. Liang JX, "An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography", J Hepatol, 79, pp.592~604 (2023)
263. Shire NJ, "Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C", J Magn Reson Imaging, 34, pp.947~955 (2011)
264. Wang J, "Assessment of advanced hepatic MR elastography methods for susceptibility artifact suppression in clinical patients", J Magn Reson Imaging, 47, pp.976~987 (2018)
265. Srinivasa Babu A, "Elastography in chronic liver disease : modalities, techniques, limitations, and future directions", Radiographics, 36, pp.1987~2006 (2016)
266. Noureddin M, "MRI-based(MAST)score accurately identifies patients with NASH and significant fibrosis", J Hepatol, 76, pp.781~787 (2022)
267. Tamaki N, "Magnetic resonance elastography plus Fibrosis-4versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis", Hepatology, 75, pp.661~672 (2022)
268. Bedogni G, "The Fatty liver index : a simple and accurate predictor of hepatic steatosis in the general population", BMC Gastroenterol, 6, pp.33~ (2006)
269. Kotronen A, "Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors", Gastroenterology, 137, pp.865~872 (2009)
270. Lee JH, "Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease", Dig Liver Dis, 42, pp.503~508 (2010)
271. Kim JH, "Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population", Liver Int, 31, pp.1600~1601 (2011)
272. Kim JH, "Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke : a large population-based study", Cardiovasc Diabetol, 19, pp.51~ (2020)
273. Cho EJ, "Fatty liver index for predicting nonalcoholic fatty liver disease in an asymptomatic Korean population", Diagnostics(Basel), 11, pp.2233~ (2021)
274. Huang X, "Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese", Medicine(Baltimore), 94, pp.e1682~ (2015)
275. Yang BL, "External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan", PLoS One, 10, pp.e0120443~ (2015)
276. Jung JY, "Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population", Hepatol Int, 13, pp.222~233 (2019)
277. Sviklāne L, "Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes", J Gastroenterol Hepatol, 33, pp.270~276 (2018)
278. Chang JW, "Hepatic steatosis index in the detection of fatty liver in patients with chronic hepatitis B receiving antiviral therapy", Gut Liver, 15, pp.117~127 (2021)
279. Chan WK, "Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease", J Gastroenterol Hepatol, 29, pp.1470~1476 (2014)
280. Chon YE, "Controlled attenuation parameter(CAP)for detection of hepatic steatosis in patients with chronic liver diseases : a prospective study of a native Korean population", Liver Int, 34, pp.102~109 (2014)
281. Eddowes PJ, "Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease", Gastroenterology, 156, pp.1717~1730 (2019)
282. Pu K, "Diagnostic accuracy of controlled attenuation parameter(CAP)as a noninvasive test for steatosis in suspected nonalcoholic fatty liver disease : a systematic review and meta-analysis", BMC Gastroenterol, 19, pp.51~ (2019)
283. Petroff D, "Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes : an individual patient data meta-analysis", Lancet Gastroenterol Hepatol, 6, pp.185~198 (2021)
284. Wong VW, "Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter", J Hepatol, 67, pp.577~584 (2017)
285. Tada T, "Usefulness of attenuation imaging with an ultrasound scanner for the evaluation of hepatic steatosis", Ultrasound Med Biol, 45, pp.2679~2687 (2019)
286. Bae JS, "Assessment of hepatic steatosis by using attenuation imaging : a quantitative, easy-to-perform ultrasound technique", Eur Radiol, 29, pp.6499~6507 (2019)
287. Ferraioli G, "US attenuation for liver fat quantification : an AIUM-RSNA QIBA pulse-echo quantitative ultrasound initiative", Radiology, 302, pp.495~506 (2022)
288. Jeon SK, "Quantitative ultrasound radiofrequency data analysis for the assessment of hepatic steatosis in nonalcoholic fatty liver disease using magnetic resonance imaging proton density fat fraction as the reference standard", Korean J Radiol, 22, pp.1077~1086 (2021)
289. Hsu PK, "Attenuation imaging with ultrasound as a novel evaluation method for liver steatosis", J Clin Med, 10, pp.965~ (2021)
290. Bao J, "A comparative study of ultrasound attenuation imaging, controlled attenuation parameters, and magnetic resonance spectroscopy for the detection of hepatic steatosis", J Ultrasound Med, 42, pp.1481~1489 (2023)
291. Fishbein M, "Hepatic MRI for fat quantitation : its relationship to fat morphology, diagnosis, and ultrasound", J Clin Gastroenterol, 39, pp.619~625 (2005)
292. Szczepaniak LS, "Magnetic resonance spectroscopy to measure hepatic triglyceride content : prevalence of hepatic steatosis in the general population", Am J Physiol Endocrinol Metab, 288, pp.E462~E468 (2005)
293. Idilman IS, "Hepatic steatosis : quantification by proton density fat fraction with MR imaging versus liver biopsy", Radiology, 267, pp.767~775 (2013)
294. Middleton MS, "Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis", Gastroenterology, 153, pp.753~761 (2017)
295. Gu J, "Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease : a meta-analysis", Eur Radiol, 29, pp.3564~3573 (2019)
296. Gu Q, "A metaanalysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease", Eur J Clin Invest, 51, pp.e13446~ (2021)
297. Boudinaud C, "Quantification of steatosis in alcoholic and nonalcoholic fatty liver disease : evaluation of four MR techniques versus biopsy", Eur J Radiol, 118, pp.169~174 (2019)
298. Devarbhavi H, "Global burden of liver disease : 2023 update", J Hepatol, 79, pp.516~537 (2023)
299. Bataller R, "Liver fibrosis in alcoholic liver disease", Semin Liver Dis, 35, pp.146~156 (2015)
300. Gómez-Medina C, "Subclinical versus advanced forms of alcohol-related liver disease : need for early detection", Clin Mol Hepatol, 29, pp.1~15 (2023)
301. Fernandez M, "Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease", Eur J Gastroenterol Hepatol, 27, pp.1074~1079 (2015)
302. Voican CS, "Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease", Liver Int, 37, pp.1697~1705 (2017)
303. Thiele M, "Accuracy of the enhanced liver fibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease", Gastroenterology, 154, pp.1369~1379 (2018)
304. Nguyen-Khac E, "Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan : prospective comparison with seven non-invasive laboratory tests", Aliment Pharmacol Ther, 28, pp.1188~1198 (2008)
305. Zhang D, "Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease using acoustic radiation force impulse elastography", Abdom Imaging, 40, pp.723~729 (2015)
306. Connoley D, "The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease : a cohort study", BMC Gastroenterol, 21, pp.268~ (2021)
307. Madsen BS, "Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar-associated protein 4", Liver Int, 40, pp.1701~1712 (2020)
308. Niu L, "Noninvasive proteomic biomarkers for alcoholrelated liver disease", Nat Med, 28, pp.1277~1287 (2022)
309. Nahon P, "Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease", J Hepatol, 49, pp.1062~1068 (2008)
310. Kim SG, "The usefulness of transient elastography to diagnose cirrhosis in patients with alcoholic liver disease", Korean J Hepatol, 15, pp.42~51 (2009)
311. Janssens F, "Can transient elastography replace liver histology for determination of advanced fibrosis in alcoholic patients : a real-life study", J Clin Gastroenterol, 44, pp.575~582 (2010)
312. Thiele M, "Transient and 2-dimensional shear-wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis", Gastroenterology, 150, pp.123~133 (2016)
313. Papatheodoridi M, "Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease", J Hepatol, 74, pp.1109~1116 (2021)
314. Pavlov CS, "Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease", Cochrane Database Syst Rev, 1, pp.CD010542~ (2015)
315. Nguyen-Khac E, "Noninvasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography : an individual patient data meta-analysis", Lancet Gastroenterol Hepatol, 3, pp.614~625 (2018)
316. Mueller S, "Inflammation-adapted liver stiffness values for improved fibrosis staging in patients with hepatitis C virus and alcoholic liver disease", Liver Int, 35, pp.2514~2521 (2015)
317. de Franchis R, "Expanding consensus in portal hypertension : report of the Baveno VI Consensus Workshop : stratifying risk and individualizing care for portal hypertension", J Hepatol, 63, pp.743~752 (2015)
318. Gelsi E, "Effect of detoxification on liver stiffness assessed by Fibroscan® in alcoholic patients", Alcohol Clin Exp Res, 35, pp.566~570 (2011)
319. Kiani A, "Acoustic radiation force impulse imaging for assessing liver fibrosis in alcoholic liver disease", World J Gastroenterol, 22, pp.4926~4935 (2016)
320. Cho Y, "Point shear wave elastography predicts fibrosis severity and steatohepatitis in alcohol-related liver disease", Hepatol Int, 14, pp.270~280 (2020)
321. Bensamoun SF, "Cutoff values for alcoholic liver fibrosis using magnetic resonance elastography technique", Alcohol Clin Exp Res, 37, pp.811~817 (2013)
322. Murillo Perez CF, "Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response", Aliment Pharmacol Ther, 50, pp.1127~1136 (2019)
323. Corpechot C, "Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis", Hepatology, 48, pp.871~877 (2008)
324. Sharma R, "Increased mortality risk in autoimmune hepatitis : a nationwide population-based cohort study with histopathology", Clin Gastroenterol Hepatol, 19, pp.2636~2647 (2021)
325. Muir AJ, "Simtuzumab for primary sclerosing cholangitis : phase 2 study results with insights on the natural history of the disease", Hepatology, 69, pp.684~698 (2019)
326. Sessa A, "From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?", JHEP Rep, 3, pp.100249~ (2021)
327. Colli A, "Decompensated chronic heart failure : increased liver stiffness measured by means of transient elastography", Radiology, 257, pp.872~878 (2010)
328. Stasi C, "Assessment of liver fibrosis in primary biliary cholangitis : comparison between indirect serum markers and fibrosis morphometry", Dig Liver Dis, 48, pp.298~301 (2016)
329. Olmez S, "The relationship between liver histology and noninvasive markers in primary biliary cirrhosis", Eur J Gastroenterol Hepatol, 28, pp.773~776 (2016)
330. Gómez-Dominguez E, "Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis", Aliment Pharmacol Ther, 27, pp.441~447 (2008)
331. Corpechot C, "Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis", Hepatology, 56, pp.198~208 (2012)
332. Koizumi Y, "Comparison between real-time tissue elastography and vibration-controlled transient elastography for the assessment of liver fibrosis and disease progression in patients with primary biliary cholangitis", Hepatol Res, 47, pp.1252~1259 (2017)
333. Floreani A, "Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis", Dig Liver Dis, 43, pp.887~892 (2011)
334. Cristoferi L, "Accuracy of transient elastography in assessing fibrosis at diagnosis in naïve patients with primary biliary cholangitis : a dual cut-off approach", Hepatology, 74, pp.1496~1508 (2021)
335. Park DW, "Diagnostic performance of a point shear wave elastography(pSWE)for hepatic fibrosis in patients with autoimmune liver disease", PLoS One, 14, pp.e0212771~ (2019)
336. Manesis EK, "Liver stiffness measurements by 2-dimensional shear wave elastography compared to histological and ultrasound parameters in primary biliary cholangitis", Scand J Gastroenterol, 56, pp.1187~1193 (2021)
337. Osman KT, "Liver stiffness measured by either magnetic resonance or transient elastography is associated with liver fibrosis and is an independent predictor of outcomes among patients with primary biliary cholangitis", J Clin Gastroenterol, 55, pp.449~457 (2021)
338. Sheptulina A, "Platelet count to spleen diameter ratio non-invasively identifies severe fibrosis and cirrhosis in patients with autoimmune hepatitis", J Gastroenterol Hepatol, 31, pp.1956~1962 (2016)
339. Xu Q, "Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis", J Gastroenterol Hepatol, 32, pp.639~644 (2017)
340. Yuan X, "Noninvasive inflammatory markers for assessing liver fibrosis stage in autoimmune hepatitis patients", Eur J Gastroenterol Hepatol, 31, pp.1467~1474 (2019)
341. Anastasiou OE, "Performance and utility of transient elastography and non-invasive markers of liver fiibrosis in patients with autoimmune hepatitis : a single centre experience", Hepat Mon, 16, pp.e40737~ (2016)
342. Wu S, "Systematic review : diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis", Hepatol Int, 13, pp.91~101 (2019)
343. Hartl J, "Transient elastography in autoimmune hepatitis : timing determines the impact of inflammation and fibrosis", J Hepatol, 65, pp.769~775 (2016)
344. Guo L, "Transient elastography(FibroScan)performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients", Med Sci Monit, 23, pp.5106~5112 (2017)
345. Paranaguá-Vezozzo DC, "Liver elastography can predict degree of advanced fibrosis for autoimmune hepatitis in biochemical remission", JGH Open, 7, pp.272~277 (2023)
346. Li C, "Diagnostic performance of shear wave elastography in patients with autoimmune liver disease", J Ultrasound Med, 38, pp.103~111 (2019)
347. Wang J, "Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis", World J Gastroenterol, 23, pp.859~868 (2017)
348. Corpechot C, "Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis", Gastroenterology, 146, pp.970~979 (2014)
349. Ehlken H, "Validation of transient elastography and comparison with spleen length measurement for staging of fibrosis and clinical prognosis in primary sclerosing cholangitis", PLoS One, 11, pp.e0164224~ (2016)
350. Eaton JE, "Performance of magnetic resonance elastography in primary sclerosing cholangitis", J Gastroenterol Hepatol, 31, pp.1184~1190 (2016)
351. Lemmer A, "Assessment of advanced liver fibrosis and the risk for hepatic decompensation in patients with congestive hepatopathy", Hepatology, 68, pp.1633~1641 (2018)
352. Wu FM, "Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients", J Heart Lung Transplant, 36, pp.211~219 (2017)
353. Wu FM, "Transient elastography may identify Fontan patients with unfavorable hemodynamics and advanced hepatic fibrosis", Congenit Heart Dis, 9, pp.438~447 (2014)
354. Shin YR, "Noninvasive surrogates are poor predictors of liver fibrosis in patients with Fontan circulation", J Thorac Cardiovasc Surg, 164, pp.1176~1185 (2022)
355. Friedrich-Rust M, "Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers", J Thorac Cardiovasc Surg, 135, pp.560~567 (2008)
356. Chon YE, "Dynamics of the liver stiffness value using transient elastography during the perioperative period in patients with valvular heart disease", PLoS One, 9, pp.e92795~ (2014)
357. Silva-Sepulveda JA, "Evaluation of Fontan liver disease : correlation of transjugular liver biopsy with magnetic resonance and hemodynamics", Congenit Heart Dis, 14, pp.600~608 (2019)
358. Serai SD, "MR elastography-based staging of liver fibrosis in Fontan procedure associated liver disease is confounded by effects of venous congestion", Clin Radiol, 77, pp.e776~e782 (2022)
359. Serra-Burriel M, "Transient elastography for screening of liver fibrosis : cost-effectiveness analysis from six prospective cohorts in Europe and Asia", J Hepatol, 71, pp.1141~1151 (2019)
360. Zhang E, "Cost-utility analysis of nonalcoholic steatohepatitis screening", Eur Radiol, 25, pp.3282~3294 (2015)
361. Graupera I, "Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population", Clin Gastroenterol Hepatol, 20, pp.2567~2576 (2022)
362. Bril F, "Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes", Diabetes Care, 43, pp.290~297 (2020)
363. Younossi ZM, "Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U. S", Diabetes Care, 43, pp.283~289 (2020)
364. Noureddin M, "Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective : a comprehensive cost-utility analysis", Gastroenterology, 159, pp.1985~1987 (2020)
365. Tapper EB, "Costeffective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography", Am J Gastroenterol, 110, pp.1298~1304 (2015)
366. Vilar-Gomez E, "Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States Health Care System", Clin Gastroenterol Hepatol, 18, pp.2305~2314 (2020)
367. Crossan C, "Referral pathways for patients with NAFLD based on non-invasive fibrosis tests : diagnostic accuracy and cost analysis", Liver Int, 39, pp.2052~2060 (2019)
368. Srivastava A, "Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease", BMC Gastroenterol, 19, pp.122~ (2019)
369. Congly SE, "Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting", PLoS One, 16, pp.e0251741~ (2021)
370. Sangha K, "Costeffectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease(NAFLD)patients with advanced fibrosis", Hepatology, 77, pp.1702~1711 (2023)
371. Asphaug L, "Cost-effectiveness of noninvasive screening for alcohol-related liver fibrosis", Hepatology, 71, pp.2093~2104 (2020)
372. van Katwyk S, "Transient elastography for the diagnosis of liver fibrosis : a systematic review of economic evaluations", Liver Int, 37, pp.851~861 (2017)
373. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
374. European Association for the Study of the Liver, "EASL 2017clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
375. Di Bisceglie AM, "Determination of hepatitis B phenotype using biochemical and serological markers", J Viral Hepat, 24, pp.320~329 (2017)
376. Yao K, "Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone", J Viral Hepat, 28, pp.1025~1033 (2021)
377. Teng W, "Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines", Hepatol Int, 15, pp.1421~1430 (2021)
378. Huang DQ, "Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase", Hepatology, 78, pp.1558~1568 (2023)
379. Liu K, "Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone", Liver Int, 39, pp.494~502 (2019)
380. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
381. Srivastava A, "Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease", J Hepatol, 71, pp.371~378 (2019)
382. Yu JH, "Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease : current and future", Clin Mol Hepatol, 29(Suppl), pp.S136~S149 (2023)
383. Cusi K, "American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings : co-sponsored by the American Association for the Study of Liver Diseases(AASLD)", Endocr Pract, 28, pp.528~562 (2022)
384. Rinella ME, "AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease", Hepatology, 77, pp.1797~1835 (2023)
385. Wang L, "Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis", PLoS One, 12, pp.e0182969~ (2017)
386. Lisotti A, "Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis", Hepatology, 59, pp.643~650 (2014)
387. Berzigotti A, "Ultrasound in portal hypertension--part 2--and EFSUMB recommendations for the performance and reporting of ultrasound examinations in portal hypertension", Ultraschall Med, 33, pp.8~32 (2012)
388. Berzigotti A, "Ultrasound in portal hypertension--part 1", Ultraschall Med, 32, pp.548~568 (2011)
389. Kim BK, "A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis", Am J Gastroenterol, 105, pp.1382~1390 (2010)
390. Berzigotti A, "Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis", Gastroenterology, 144, pp.102~111 (2013)
391. You MW, "A meta-analysis for the diagnostic performance of transient elastography for clinically significant portal hypertension", Ultrasound Med Biol, 43, pp.59~68 (2017)
392. Garcia-Tsao G, "Portal hypertensive bleeding in cirrhosis : risk stratification, diagnosis, and management : 2016 practice guidance by the American Association for the study of liver diseases", Hepatology, 65, pp.310~335 (2017)
393. Castera L, "Non invasive evaluation of portal hypertension using transient elastography", J Hepatol, 56, pp.696~703 (2012)
394. Augustin S, "Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease : a prospective study", J Hepatol, 60, pp.561~569 (2014)
395. Bureau C, "Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease", Aliment Pharmacol Ther, 27, pp.1261~1268 (2008)
396. Robic MA, "Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease : a prospective study", J Hepatol, 55, pp.1017~1024 (2011)
397. Vergniol J, "Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C", Gastroenterology, 140, pp.1970~1979 (2011)
398. Vizzutti F, "Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis", Hepatology, 45, pp.1290~1297 (2007)
399. Berzigotti A, "Non-invasive evaluation of portal hypertension using ultrasound elastography", J Hepatol, 67, pp.399~411 (2017)
400. Abraldes JG, "Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis : the"Anticipate"study", Hepatology, 64, pp.2173~2184 (2016)
401. Korean Association for the Study of the Liver(KASL), "KASL clinical practice guidelines for liver cirrhosis : varices, hepatic encephalopathy, and related complications", Clin Mol Hepatol, 26, pp.83~127 (2020)
402. Shi KQ, "Transient elastography : a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease", Liver Int, 33, pp.62~71 (2013)
403. Maurice JB, "Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices", J Hepatol, 65, pp.899~905 (2016)
404. Marot A, "Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding", Liver Int, 37, pp.707~716 (2017)
405. Lee HA, "Prediction of the varices needing treatment with non-invasive tests in patients with compensated advanced chronic liver disease", Liver Int, 39, pp.1071~1079 (2019)
406. Kang SH, "Application of Baveno criteria and modified Baveno criteria with shear-wave elastography in compensated advanced chronic liver disease", J Korean Med Sci, 35, pp.e249~ (2020)
407. Joyce DP, "Laparoscopic resection of giant pseudodiverticulum-a video vignette", Colorectal Dis, 19, pp.305~306 (2017)
408. Augustin S, "Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease", Hepatology, 66, pp.1980~1988 (2017)
409. Takuma Y, "Portal hypertension in patients with liver cirrhosis : diagnostic accuracy of spleen stiffness", Radiology, 279, pp.609~619 (2016)
410. Salzl P, "Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index", Ultraschall Med, 35, pp.528~533 (2014)
411. Attia D, "Evaluation of liver and spleen stiffness with acoustic radiation force impulse quantification elastography for diagnosing clinically significant portal hypertension", Ultraschall Med, 36, pp.603~610 (2015)
412. Suh CH, "Shear wave elastography as a quantitative biomarker of clinically significant portal hypertension : a systematic review and meta-analysis", AJR Am J Roentgenol, 210, pp.W185~W195 (2018)
413. Matsui N, "Magnetic resonance elastography increases usefulness and safety of non-invasive screening for esophageal varices", J Gastroenterol Hepatol, 33, pp.2022~2028 (2018)
414. Singh S, "Accuracy of spleen stiffness measurement in detection of esophageal varices in patients with chronic liver disease : systematic review and meta-analysis", Clin Gastroenterol Hepatol, 12, pp.935~945 (2014)
415. Stefanescu H, "Modified spleen stiffness measurement : a step forward, but still not the solution to all problems in the noninvasive assessment of cirrhotic patients", J Viral Hepat, 21, pp.e54~ (2014)
416. Calvaruso V, "Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis", J Viral Hepat, 20, pp.867~874 (2013)
417. Cassinotto C, "Liver and spleen elastography using supersonic shear imaging for the non-invasive diagnosis of cirrhosis severity and oesophageal varices", Dig Liver Dis, 47, pp.695~701 (2015)
418. Lantinga MA, "Spleen stiffness measurement across the spectrum of liver disease patients in real-world practice", J Clin Exp Hepatol, 13, pp.414~427 (2023)
419. Thabut D, "Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy", Gastroenterology, 156, pp.997~1009 (2019)
420. Reverter E, "Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis", Liver Int, 39, pp.705~713 (2019)
421. Yang S, "The role of STAT3", mTOR-regulated autophagy in angiotensin IIinduced senescence of human glomerular mesangial cells, 2019, pp.53, 327~338
422. Kim JH, "Noninvasive tests for fibrosis predict 5-year mortality and hepatocellular carcinoma in patients with chronic hepatitis B", J Clin Gastroenterol, 50, pp.882~888 (2016)
423. Kim MN, "Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gammaglutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients : comparison with liver biopsy", Eur J Gastroenterol Hepatol, 32, pp.433~439 (2020)
424. Shin SK, "Partial virological response after 2 years of entecavir therapy increases the risk of hepatocellular carcinoma in patients with hepatitis B virus-associated cirrhosis", Gut Liver, 15, pp.430~439 (2021)
425. Suh B, "High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers", Hepatology, 61, pp.1261~1268 (2015)
426. Jeong J, "Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment-naïve patients with chronic hepatitis B following entecavir therapy", Hepatol Res, 51, pp.923~932 (2021)
427. Chun HS, "Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C", Eur J Gastroenterol Hepatol, 32, pp.378~385 (2020)
428. Alonso López S, "A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis", Hepatology, 72, pp.1924~1934 (2020)
429. Ioannou GN, "Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores", Gastroenterology, 157, pp.1264~1278 (2019)
430. Younes R, "Long-term outcomes and predictive ability of non-invasive scoring systems in patients with nonalcoholic fatty liver disease", J Hepatol, 75, pp.786~794 (2021)
431. Kim JH, "Validation of modified fibrosis-4 index for predicting hepatocellular carcinoma in patients with compensated alcoholic liver cirrhosis", Medicine(Baltimore), 97, pp.e13438~ (2018)
432. Cholankeril G, "Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in nonalcoholic fatty liver disease", J Hepatol, 78, pp.493~500 (2023)
433. Kim SU, "Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development", Liver Int, 37, pp.879~887 (2017)
434. Lee K, "Prediction of the risk of hepatocellular carcinoma in chronic hepatitis C patients after sustained virological response by aspartate aminotransferase to platelet ratio index", Gut Liver, 10, pp.796~802 (2016)
435. Liang LY, "Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma", Aliment Pharmacol Ther, 49, pp.1509~1517 (2019)
436. Singh S, "Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 11, pp.1573~1584 (2013)
437. Wang J, "Liver stiffness measurement predicted liver-related events and allcause mortality : a systematic review and nonlinear doseresponse meta-analysis", Hepatol Commun, 2, pp.467~476 (2018)
438. Shen Y, "The prognostic role of liver stiffness in patients with chronic liver disease : a systematic review and dose-response meta-analysis", Hepatol Int, 13, pp.560~572 (2019)
439. Wong GL, "Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B", J Hepatol, 60, pp.339~345 (2014)
440. Seo YS, "Risk assessment of hepatocellular carcinoma using transient elastography vs. liver biopsy in chronic hepatitis B patients receiving antiviral therapy", Medicine(Baltimore), 95, pp.e2985~ (2016)
441. Kim MN, "Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis", Hepatology, 61, pp.1851~1859 (2015)
442. Kim BS, "Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis", J Gastroenterol Hepatol, 33, pp.503~510 (2018)
443. Kim BK, "Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy", Liver Int, 33, pp.180~189 (2013)
444. Jung KS, "Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement(FibroScan)", Hepatology, 53, pp.885~894 (2011)
445. Jeon MY, "Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis", Hepatol Int, 11, pp.268~276 (2017)
446. Lee HW, "Predicting liver-related events using transient elastography in chronic hepatitis C patients with sustained virological response", Gut Liver, 10, pp.429~436 (2016)
447. Nakai M, "Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication", Sci Rep, 12, pp.1449~ (2022)
448. Liu YC, "Comparing predictability of non-invasive tools for hepatocellular carcinoma in treated chronic hepatitis C patients", Dig Dis Sci, 68, pp.323~332 (2023)
449. Tada T, "Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response", Hepatol Res, 51, pp.860~869 (2021)
450. Pons M, "Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals", J Hepatol, 72, pp.472~480 (2020)
451. Degasperi E, "Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection", Clin Gastroenterol Hepatol, 17, pp.1183~1191 (2019)
452. Ampuero J, "A 2-step strategy combining FIB-4 with transient elastography and ultrasound predicted liver cancer after HCV cure", Am J Gastroenterol, 117, pp.138~146 (2022)
453. Petta S, "Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease", Clin Gastroenterol Hepatol, 19, pp.806~815 (2021)
454. Rasmussen DN, "Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease", J Hepatol, 75, pp.1017~1025 (2021)
455. Zhang T, "APS(age, platelets, 2D shear-wave elastography)score predicts hepatocellular carcinoma in chronic hepatitis B", Radiology, 301, pp.350~359 (2021)
456. Jeong JY, "Role of shear wave elastography in evaluating the risk of hepatocellular carcinoma in patients with chronic hepatitis B", Gut Liver, 11, pp.852~859 (2017)
457. Hamada K, "Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response", PLoS One, 13, pp.e0195173~ (2018)
458. Higuchi M, "Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality", Aliment Pharmacol Ther, 55, pp.292~301 (2022)
459. Lee DH, "Prognostic role of liver stiffness measurements using magnetic resonance elastography in patients with compensated chronic liver disease", Eur Radiol, 28, pp.3513~3521 (2018)
460. Higuchi M, "Prediction of hepatocellular carcinoma after sustained virological responses using magnetic resonance elastography", Clin Gastroenterol Hepatol, 17, pp.2616~2618 (2019)
461. Kim DY, "Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma : development and validation of a predictive model", Onco Targets Ther, 6, pp.1463~1469 (2013)
462. Shin SH, "Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection : comparison with histological fibrosis", Liver Int, 35, pp.1054~1062 (2015)
463. Lee HW, "An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia", Liver Int, 40, pp.1736~1743 (2020)
464. Chon HY, "Predictive performance of CAGE-B and SAGE-B models in Asian treatment-naive patients who started entecavir for chronic hepatitis B", Clin Gastroenterol Hepatol, 20, pp.e794~e807 (2022)
465. Lee HW, "Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy", Am J Gastroenterol, 109, pp.1241~1249 (2014)
466. Chon HY, "Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B", Eur J Gastroenterol Hepatol, 33, pp.885~893 (2021)
467. Chon HY, "Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma", Aliment Pharmacol Ther, 53, pp.919~927 (2021)
468. Lee JS, "Liver stiffness-based risk prediction model for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease", Cancers(Basel), 13, pp.4567~ (2021)
469. Toyoda H, "A laboratory marker, FIB-4 index, as a predictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection", Surgery, 157, pp.699~707 (2015)
470. Okamura Y, "The FIB-4 index is a significant prognostic factor in patients with non-B non-C hepatocellular carcinoma after curative surgery", Langenbecks Arch Surg, 401, pp.195~203 (2016)
471. Yun SO, "Fibrosis-4 index, a predictor for prognosis of hepatocellular carcinoma patients after curative hepatectomy even in hepatitis B virus dominant populations", Ann Surg Treat Res, 104, pp.195~204 (2023)
472. Yanagaki M, "Novel combined fibrosis-based index predicts the longterm outcomes of hepatocellular carcinoma after hepatic resection", Int J Clin Oncol, 27, pp.717~728 (2022)
473. Liao R, "Combined preoperative ALBI and FIB-4 is associated with recurrence of hepatocellular carcinoma after curative hepatectomy", J Gastrointest Surg, 22, pp.1679~1687 (2018)
474. Wong JS, "Liver stiffness measurement by transient elastography as a predictor on posthepatectomy outcomes", Ann Surg, 257, pp.922~928 (2013)
475. Wang JH, "Liver stiffness and insulin resistance in predicting recurrence for early stage hepatoma patients after curative resection", Sci Rep, 11, pp.6041~ (2021)
476. Tortajada P, "Resectable and transplantable hepatocellular carcinoma : integration of liver stiffness assessment in the decision-making algorithm", Surgery, 172, pp.1704~1711 (2022)
477. Rajakannu M, "Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinoma", Surgery, 162, pp.766~774 (2017)
478. Qi M, "Clinical significance of preoperative liver stiffness measurements in primary HBV-positive hepatocellular carcinoma", Future Oncol, 13, pp.2799~2810 (2017)
479. Jung KS, "Prediction of recurrence after curative resection of hepatocellular carcinoma using liver stiffness measurement(FibroScan ®)", Ann Surg Oncol, 19, pp.4278~4286 (2012)
480. Kim SU, "Prediction of postoperative hepatic insufficiency by liver stiffness measurement(FibroScan®)before curative resection of hepatocellular carcinoma : a pilot study", Hepatol Int, 2, pp.471~477 (2008)
481. Lei JW, "Prediction of posthepatectomy liver failure using transient elastography in patients with hepatitis B related hepatocellular carcinoma", BMC Gastroenterol, 17, pp.171~ (2017)
482. Serenari M, "A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma", J Hepatol, 73, pp.855~862 (2020)
483. Jung KS, "Liver stiffness value-based risk estimation of late recurrence after curative resection of hepatocellular carcinoma : development and validation of a predictive model", PLoS One, 9, pp.e99167~ (2014)
484. Long H, "Liver stiffness measured by two-dimensional shear wave elastography for predicting symptomatic post-hepatectomy liver failure in patients with hepatocellular carcinoma", Ann Surg Oncol, 29, pp.327~336 (2022)
485. Long H, "Predicting symptomatic post-hepatectomy liver failure in patients with hepatocellular carcinoma : development and validation of a preoperative nomogram", Eur Radiol, 33, pp.7665~7674 (2023)
486. Abe H, "Magnetic resonance elastography-based prediction of hepatocellular carcinoma recurrence after curative resection", Surgery, 170, pp.167~172 (2021)
487. Sato N, "Prediction of major complications after hepatectomy using liver stiffness values determined by magnetic resonance elastography", Br J Surg, 105, pp.1192~1199 (2018)
488. Yoon JS, "Comparison of acoustic radiation force impulse elastography and transient elastography for prediction of hepatocellular carcinoma recurrence after radiofrequency ablation", Eur J Gastroenterol Hepatol, 30, pp.1230~1236 (2018)
489. Lee PC, "Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation", Sci Rep, 10, pp.2006~ (2020)
490. Lee YR, "Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation", J Gastroenterol Hepatol, 32, pp.1079~1086 (2017)
491. Lee SH, "Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma", Onco Targets Ther, 8, pp.347~356 (2015)
492. Rekik S, "Transient elastography predicts survival after radiofrequency ablation of hepatocellular carcinoma developing on cirrhosis", J Gastroenterol Hepatol, 35, pp.142~150 (2020)
493. Sanyal AJ, "The natural history of advanced fibrosis due to nonalcoholic steatohepatitis : data from the simtuzumab trials", Hepatology, 70, pp.1913~1927 (2019)
494. Mayo MJ, "Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay", Hepatology, 48, pp.1549~1557 (2008)
495. Chiang HH, "A combination of the on-treatment FIB-4 and alphafoetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir", Liver Int, 38, pp.1997~2005 (2018)
496. Angulo P, "Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 145, pp.782~789 (2013)
497. Kuo YH, "Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus", Kaohsiung J Med Sci, 38, pp.268~276 (2022)
498. Macías J, "Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV", hepatitis C virus-coinfected patients, 2013, pp.27, 2541~2549
499. Kim SU, "Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis", PLoS One, 7, pp.e36676~ (2012)
500. Kim BK, "Risk assessment of development of hepatic decompensation in histologically proven hepatitis B viral cirrhosis using liver stiffness measurement", Digestion, 85, pp.219~227 (2012)
501. Vutien P, "Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes", Aliment Pharmacol Ther, 52, pp.1717~1727 (2020)
502. Rodprasert N, "Association between liver stiffness and liver-related events in HCV-infected patients after successful treatment with direct-acting antivirals", Medicina(Kaunas), 59, pp.602~ (2023)
503. Shili-Masmoudi S, "Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease", Liver Int, 40, pp.581~589 (2020)
504. Trebicka J, "Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease", Gut, 71, pp.402~414 (2022)
505. Seo YG, "Fibrosis-4index predicts long-term allcause, cardiovascular and liverrelated mortality in the adult Korean population", Clin Gastroenterol Hepatol, 21, pp.3322~3335 (2023)
506. Sohn W, "Liver fibrosis scores and risk of liver-related mortality in young adults with chronic hepatitis B : a cohort study", J Viral Hepat, 29, pp.69~77 (2022)
507. Lee J, "Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events : a systematic review", Liver Int, 41, pp.261~270 (2021)
508. Chang Y, "Alcoholic and nonalcoholic fatty liver disease and liver-related mortality : a cohort study", Am J Gastroenterol, 114, pp.620~629 (2019)
509. Zhang Y, "FIB-4 index serves as a noninvasive prognostic biomarker in patients with hepatocellular carcinoma : a meta-analysis", Medicine(Baltimore), 97, pp.e13696~ (2018)
510. Zhang Y, "Prognostic value of aspartate aminotransferase to platelet ratio index as a noninvasive biomarker in patients with hepatocellular carcinoma : a meta-analysis", Cancer Manag Res, 10, pp.3023~3032 (2018)
511. Lee DH, "Liver stiffness measured by two-dimensional shear-wave elastography : prognostic value after radiofrequency ablation for hepatocellular carcinoma", Liver Cancer, 7, pp.65~75 (2018)
512. Xie X, "Prognosis value of liver stiffness measurements by 2D-SWE in primary HBV-positive hepatocellular carcinoma following radiofrequency ablation", Transl Cancer Res, 9, pp.2518~2526 (2020)
513. Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5-year openlabel follow-up study", Lancet, 381, pp.468~475 (2013)
514. Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5years", Gastroenterology, 131, pp.1743~1751 (2006)
515. Chang TT, "Long-term entecavir therapy results in the reversal of fibrosis", cirrhosis and continued histological improvement in patients with chronic hepatitis B, 2010, pp.52, 886~893
516. Kim JH, "Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment", Liver Int, 35, pp.1103~1115 (2015)
517. Facciorusso A, "Systematic review with metaanalysis : change in liver stiffness during anti-viral therapy in patients with hepatitis B", Dig Liver Dis, 50, pp.787~794 (2018)
518. Dong XQ, "Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B : a 78-week prospective study", J Gastroenterol Hepatol, 34, pp.755~763 (2019)
519. Xu W, "FibroScan predicts liver fibrosis progression in chronic HBV infection patients with no clear indication for antiviral therapy : a retrospective cohort study", Infect Drug Resist, 16, pp.1777~1785 (2023)
520. Wong GL, "Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B : a prospective cohort study with paired transient elastography examination", J Gastroenterol Hepatol, 28, pp.1842~1848 (2013)
521. Delle Monache M, "Noninvasive evaluation of liver fibrosis in a sample of putative inactive HBV carriers in Rome, Italy", Can J Infect Dis Med Microbiol, 2021, pp.3068690~ (2021)
522. Liu R, "Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy", Clin Exp Med, 19, pp.309~320 (2019)
523. Li Q, "Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy", Clin Exp Med, 18, pp.273~282 (2018)
524. Chon YE, "Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B", J Gastroenterol Hepatol, 37, pp.200~207 (2022)
525. Kim WR, "Evaluation of APRI and FIB-4 scoring systems for noninvasive assessment of hepatic fibrosis in chronic hepatitis B patients", J Hepatol, 64, pp.773~780 (2016)
526. Wu SD, "Longitudinal monitoring of liver stiffness by acoustic radiation force impulse imaging in patients with chronic hepatitis B receiving entecavir", Clin Res Hepatol Gastroenterol, 42, pp.227~236 (2018)
527. Singh S, "Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 16, pp.27~38 (2018)
528. Persico M, "Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis", Antivir Ther, 23, pp.129~138 (2018)
529. Mauro E, "Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C", Hepatology, 67, pp.1683~1694 (2018)
530. Tada T, "Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response", J Gastroenterol Hepatol, 32, pp.1982~1988 (2017)
531. Kobayashi N, "Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response", Eur J Gastroenterol Hepatol, 30, pp.546~551 (2018)
532. Facciorusso A, "Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy : results from a 5-year cohort study", J Gastroenterol Hepatol, 33, pp.942~949 (2018)
533. Dolmazashvili E, "Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia : results of hepatology clinic HEPA experience", Eur J Gastroenterol Hepatol, 29, pp.1223~1230 (2017)
534. Attia D, "Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens", Eur J Gastroenterol Hepatol, 31, pp.67~74 (2019)
535. Andersen ES, "Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C", Eur J Gastroenterol Hepatol, 23, pp.41~44 (2011)
536. Alem SA, "Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation : Egyptian cohort", J Med Virol, 90, pp.1508~1515 (2018)
537. Archer AJ, "EASL clinical practice guidelines : non-invasive liver tests for evaluation of liver disease severity and prognosis", Frontline Gastroenterol, 13, pp.436~439 (2022)
538. D’Ambrosio R, "The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response", J Hepatol, 59, pp.251~256 (2013)
539. Tachi Y, "Liver stiffness measurement using acoustic radiation force impulse elastography in hepatitis C virus-infected patients with a sustained virological response", Aliment Pharmacol Ther, 44, pp.346~355 (2016)
540. Tachi Y, "Liver stiffness reduction correlates with histological characteristics of hepatitis C patients with sustained virological response", Liver Int, 38, pp.59~67 (2018)
541. Knop V, "Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus(HCV)-associated liver disease and sustained virologic response(SVR) : 3 years follow-up of a prospective longitudinal study", J Viral Hepat, 28, pp.1604~1613 (2021)
542. Forestier N, "Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C", J Gastrointestin Liver Dis, 21, pp.367~373 (2012)
543. Chen SH, "Performance of acoustic radiation force impulse elastography for staging liver fibrosis in patients with chronic hepatitis C after viral eradication", Clin Infect Dis, 70, pp.114~122 (2020)
544. Thanapirom K, "Non-invasive tests for liver fibrosis assessment in patients with chronic liver diseases : a prospective study", Sci Rep, 12, pp.4913~ (2022)
545. Tada T, "Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy", Aliment Pharmacol Ther, 47, pp.1012~1022 (2018)
546. Chuaypen N, "Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging : role of metabolic derangement and host genetic variants", PLoS One, 17, pp.e0269641~ (2022)
547. Arsik I, "Alanine aminotransferase as a monitoring biomarker in children with nonalcoholic fatty liver disease : a secondary analysis using TONIC trial data", Children(Basel), 5, pp.64~ (2018)
548. Loomba R, "Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis", Gastroenterology, 156, pp.88~95 (2019)
549. Siddiqui MS, "Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage", Clin Gastroenterol Hepatol, 17, pp.1877~1885 (2019)
550. Balkhed W, "Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease : a longterm follow-up study", Liver Int, 42, pp.1545~1556 (2022)
551. Agarwal L, "Bariatric surgery in nonalcoholic fatty liver disease(NAFLD) : impact assessment using paired liver biopsy and fibroscan", Obes Surg, 31, pp.617~626 (2021)
552. Nogami A, "Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in nonalcoholic fatty liver disease", Hepatol Res, 49, pp.872~880 (2019)
553. Sanyal AJ, "Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis", Hepatology, 75, pp.1235~1246 (2022)
554. Rinella ME, "Noninvasive evaluation of response to obeticholic acid in patients with NASH : results from the REGENERATE study", J Hepatol, 76, pp.536~548 (2022)
555. Vali Y, "Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease(the LITMUS project) : a comparative diagnostic accuracy study", Lancet Gastroenterol Hepatol, 8, pp.714~725 (2023)
556. Noureddin M, "Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials", Hepatology, 58, pp.1930~1940 (2013)
557. Idilman IS, "Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease", Scand J Gastroenterol, 49, pp.617~624 (2014)
558. Stine JG, "Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 19, pp.2274~2283 (2021)
559. Konerman MA, "Pharmacotherapy for NASH : current and emerging", J Hepatol, 68, pp.362~375 (2018)
560. Jeon SK, "Prospective evaluation of hepatic steatosis using ultrasound attenuation imaging in patients with chronic liver disease with magnetic resonance imaging proton density fat fraction as the reference standard", Ultrasound Med Biol, 45, pp.1407~1416 (2019)
561. Imajo K, "Utility of ultrasound-guided attenuation parameter for grading steatosis with reference to MRI-PDFF in a large cohort", Clin Gastroenterol Hepatol, 20, pp.2533~2541 (2022)
562. Ferraioli G, "Detection of liver steatosis with a novel ultrasound-based technique : a pilot study using MRI-derived proton density fat fraction as the gold standard", Clin Transl Gastroenterol, 10, pp.e00081~ (2019)
563. Ajmera VH, "Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease", Hepatology, 71, pp.849~860 (2020)
564. Gidener T, "Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD", Hepatology, 77, pp.268~274 (2023)
565. Jayakumar S, "Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis : analysis of data from a phase II trial of selonsertib", J Hepatol, 70, pp.133~141 (2019)
566. Rhodes FA, "Systematic review : investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease", J Gastroenterol Hepatol, 36, pp.1435~1449 (2021)
567. Hartl J, "Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis", J Hepatol, 68, pp.754~763 (2018)
568. Kowdley KV, "Application of the latest advances in evidencebased medicine in primary biliary cholangitis", Am J Gastroenterol, 118, pp.232~242 (2023)
569. Bowlus CL, "AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma", Hepatology, 77, pp.659~702 (2023)
570. Eaton JE, "Changes in liver stiffness, measured by magnetic resonance elastography, associated with hepatic decompensation in patients with primary sclerosing cholangitis", Clin Gastroenterol Hepatol, 18, pp.1576~1583 (2020)
571. Ehlken H, "Transient elastography in primary sclerosing cholangitis-the value as a prognostic factor and limitations", Gastroenterology, 147, pp.542~543 (2014)
572. Vesterhus M, "Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis", Hepatology, 62, pp.188~197 (2015)
573. Vesterhus M, "Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis", J Hepatol, 66, pp.1214~1222 (2017)
574. de Vries EMG, "Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multicentre study", Liver Int, 37, pp.1554~1561 (2017)
575. Gou YZ, "The diagnostic value of ultrasound elastography in patients with hepatitis B virus infection : a prospective study", J Int Med Res, 38, pp.2117~2125 (2010)
576. Enomoto M, "Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B : regression of liver stiffness during entecavir therapy", Hepatol Res, 40, pp.853~861 (2010)
577. Kim SU, "Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B : impact of antiviral treatment on fibrosis regression", Hepatol Int, 4, pp.673~680 (2010)
578. Wong GL, "On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients", Antivir Ther, 16, pp.165~172 (2011)
579. Fung J, "Mildto-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B", Am J Gastroenterol, 106, pp.492~496 (2011)
580. Lim SG, "Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B", Hepatogastroenterology, 58, pp.539~545 (2011)
581. Fung J, "Significant changes in liver stiffness measurements in patients with chronic hepatitis B : 3-year follow-up study", J Viral Hepat, 18, pp.e200~e205 (2011)
582. Ogawa E, "Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog", Hepatol Res, 41, pp.1178~1188 (2011)
583. Osakabe K, "Reduction of liver stiffness by antiviral therapy in chronic hepatitis B", J Gastroenterol, 46, pp.1324~1334 (2011)
584. Yan LB, "Impact of mild to moderate elevations of alanine aminotransferase on liver stiffness measurement in chronic hepatitis B patients during antiviral therapy", Hepatol Res, 43, pp.185~191 (2013)
585. Kim MN, "Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir", Liver Int, 34, pp.1216~1223 (2014)
586. Wong GL, "Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen : a prospective cohort study with paired transient elastography examination", J Gastroenterol Hepatol, 28, pp.1762~1769 (2013)
587. Yang X, "Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks", Eur J Gastroenterol Hepatol, 26, pp.396~403 (2014)
588. Kim JK, "Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents", J Korean Med Sci, 29, pp.570~575 (2014)
589. Zhang YP, "Relationships between transient elastography values and liver fibrosis in chronic liver disease patients with normal or mildly abnormal aminotransferase levels", Genet Mol Res, 14, pp.18172~18180 (2015)
590. Wang HM, "Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients", J Gastroenterol Hepatol, 31, pp.1307~1314 (2016)
591. Chon YE, "Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis", Am J Gastroenterol, 112, pp.882~891 (2017)
592. Zeng J, "Dynamic changes in liver stiffness measured by transient elastography predict clinical outcomes among patients with chronic hepatitis B", J Ultrasound Med, 36, pp.261~268 (2017)
593. Stasi C, "Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment : a preliminary study", Eur J Pharmacol, 806, pp.105~109 (2017)
594. Liang X, "Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy : a 2-year prospective study", J Viral Hepat, 25, pp.296~305 (2018)
595. Wu SD, "Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment", Clin Exp Med, 18, pp.433~443 (2018)
596. Wei S, "Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase : a retrospective study", BMC Gastroenterol, 22, pp.387~ (2022)
597. Hu M, "Effective analysis of antiviral treatment in patients with HBeAgseropositive chronic hepatitis B with ALT < 2 upper limits of normal : a multi-center retrospective cohort study", Infect Dis Ther, 12, pp.637~647 (2023)
598. Ozdogan E, "Liver fibrosis in children : a comprehensive review of mechanisms, diagnosis, and therapy", Clin Exp Pediatr, 66, pp.110~124 (2023)
599. Nobili V, "Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy : coincidence or comorbidity?", Pediatr Obes, 9, pp.e99~e102 (2014)
600. Molleston JP, "Obese children with steatohepatitis can develop cirrhosis in childhood", Am J Gastroenterol, 97, pp.2460~2462 (2002)
601. Shah I, "Correlation of APRI index with metavir index in children with neonatal cholestasis without biliary atresia", Ann Hepatol, 17, pp.592~595 (2018)
602. Grieve A, "Aspartate aminotransferase-to-platelet ratio index(APRi)in infants with biliary atresia : prognostic value at presentation", J Pediatr Surg, 48, pp.789~795 (2013)
603. Galal SM, "Noninvasive assessment of liver fibrosis in children with chronic hepatitis C : shear wave elastography and APRI versus liver biopsy", Arab J Gastroenterol, 21, pp.253~259 (2020)
604. Mansoor S, "The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease", Dig Dis Sci, 60, pp.1440~1447 (2015)
605. Mosca A, "Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease", Liver Int, 39, pp.2317~2329 (2019)
606. Mosca A, "Non-invasive diagnostic test for advanced fibrosis in adolescents with non-alcoholic fatty liver disease", Front Pediatr, 10, pp.885576~ (2022)
607. Barakat NH, "Prediction and staging of hepatic fibrosis in children with hepatitis C virus : a machine learning approach", Healthc Inform Res, 25, pp.173~181 (2019)
608. Luo H, "Assessment of liver fibrosis by transient elastography and multiparameters model in young children with chronic hepatitis B virus infection", BMC Infect Dis, 22, pp.160~ (2022)
609. Chen S, "Development and validation of noninvasive models in predicting advanced fibrosis of choledochal cyst", Pediatr Surg Int, 39, pp.87~ (2023)
610. Umetsu S, "Usefulness of serum Wisteria floribunda agglutinin-positive Mac-2binding protein in children with primary sclerosing cholangitis", Hepatol Res, 48, pp.355~363 (2018)
611. Shiau H, "Biopsy validated study of biomarkers for liver fibrosis and transplant prediction in inherited cholestasis", Hepatol Commun, 4, pp.1516~1526 (2020)
612. Mercedes R, "A liver biopsy validation pilot study of shear wave elastography, APRI, FIB-4, and novel serum biomarkers for liver fibrosis staging in children with chronic viral hepatitis", Glob Pediatr Health, 7, pp.2333794X20938931~ (2020)
613. Alkhouri N, "The development of the pediatric NAFLD fibrosis score(PNFS)to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease", PLoS One, 9, pp.e104558~ (2014)
614. Yang HR, "Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease", World J Gastroenterol, 18, pp.1525~1530 (2012)
615. Nobili V, "The pediatric NAFLD fibrosis index : a predictor of liver fibrosis in children with non-alcoholic fatty liver disease", BMC Med, 7, pp.21~ (2009)
616. Alkhouri N, "A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis", Clin Gastroenterol Hepatol, 9, pp.150~155 (2011)
617. Alkhouri N, "Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease", Liver Int, 33, pp.79~85 (2013)
618. Lee CK, "Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort : the Boston children’s hospital experience", J Pediatr, 163, pp.1058~1064 (2013)
619. Hartley JL, "Hyaluronic acid predicts hepatic fibrosis in children with hepatic disease", J Pediatr Gastroenterol Nutr, 43, pp.217~221 (2006)
620. Fitzpatrick E, "Transient elastography is a useful noninvasive tool for the evaluation of fibrosis in paediatric chronic liver disease", J Pediatr Gastroenterol Nutr, 56, pp.72~76 (2013)
621. Yamana H, "Clinical significance of the Mac-2 binding protein glycosylated isomer as a surrogate marker of graft fibrosis after pediatric liver transplantation", Transplant Proc, 55, pp.930~933 (2023)
622. Watanabe S, "Long-term results of splenomegaly after surgery for biliary atresia in the native liver", Asian J Surg, 45, pp.849~853 (2022)
623. Wang Y, "Diagnostic value of serum procollagen III N-terminal peptide for liver fibrosis in infantile cholestasis", Front Pediatr, 8, pp.131~ (2020)
624. Pereira TN, "Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease", J Hepatol, 41, pp.576~583 (2004)
625. Nobili V, "Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease", Transl Res, 156, pp.229~234 (2010)
626. Lebensztejn DM, "Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with nonalcoholic fatty liver disease", Acta Biochim Pol, 58, pp.563~566 (2011)
627. Lebensztejn DM, "Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B", Hepatology, 39, pp.868~869 (2004)
628. Chen H, "Twodimensional shear wave elastography predicts liver fibrosis in jaundiced infants with suspected biliary atresia : a prospective study", Korean J Radiol, 22, pp.959~969 (2021)
629. Ueno T, "Impact of serum autotaxin level correlating with histological findings in biliary atresia", J Pediatr Surg, 56, pp.1174~1178 (2021)
630. Lebensztejn DM, "Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B", Adv Med Sci, 52, pp.120~124 (2007)
631. Mandelia C, "Plasma cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease", J Pediatr Gastroenterol Nutr, 63, pp.181~187 (2016)
632. Manco M, "Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease", Pediatr Res, 91, pp.1781~1786 (2022)
633. Ueno T, "Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia", J Pediatr Surg, 57, pp.1215~1220 (2022)
634. Ueno T, "Clinical implications of serum Mac-2-binding protein(M2BPGi)during regular follow-up of patients with biliary atresia", Pediatr Surg Int, 34, pp.1065~1071 (2018)
635. Mjelle AB, "Normal liver stiffness values in children : a comparison of three different elastography methods", J Pediatr Gastroenterol Nutr, 68, pp.706~712 (2019)
636. Tokuhara D, "Transient elastographybased liver stiffness age-dependently increases in children", PLoS One, 11, pp.e0166683~ (2016)
637. Brunnert L, "Pediatric percentiles for transient elastography measurements-effects of age, sex, weight status and pubertal stage", Front Endocrinol(Lausanne), 13, pp.1030809~ (2022)
638. Teufel-Schäfer U, "Transient elastography correlated to four different histological fibrosis scores in children with liver disease", Eur J Pediatr, 180, pp.2237~2244 (2021)
639. Shen QL, "Assessment of liver fibrosis by Fibroscan as compared to liver biopsy in biliary atresia", World J Gastroenterol, 21, pp.6931~6936 (2015)
640. Shin NY, "Transient elastography and sonography for prediction of liver fibrosis in infants with biliary atresia", J Ultrasound Med, 33, pp.853~864 (2014)
641. Nobili V, "Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis", Hepatology, 48, pp.442~448 (2008)
642. Kim DW, "Diagnostic performance of ultrasound elastography for evaluating portal hypertension in children : a systematic review and meta-analysis", J Ultrasound Med, 38, pp.747~759 (2019)
643. Hwang JY, "Diagnostic performance of transient elastography for liver fibrosis in children : a systematic review and meta-analysis", AJR Am J Roentgenol, 211, pp.W257~W266 (2018)
644. Cetinic I, "Ultrasound shear wave elastography, shear wave dispersion and attenuation imaging of pediatric liver disease with histological correlation", Children(Basel), 9, pp.692~ (2022)
645. Kim JR, "The diagnostic performance of shear-wave elastography for liver fibrosis in children and adolescents : a systematic review and diagnostic meta-analysis", Eur Radiol, 28, pp.1175~1186 (2018)
646. Dardanelli EP, "Bidimensional shear-wave elastography for assessing liver fibrosis in children : a proposal of reference values that correlate with the histopathological Knodell-Ishak score", Pediatr Radiol, 50, pp.817~826 (2020)
647. Gao Y, "Clinical study of the value of shear wave elastography in evaluating the degree of liver fibrosis in children", Abdom Radiol(NY), 48, pp.1298~1305 (2023)
648. Garcovich M, "Liver stiffness in pediatric patients with fatty liver disease : diagnostic accuracy and reproducibility of shearwave elastography", Radiology, 283, pp.820~827 (2017)
649. Trout AT, "Liver shear wave speed and other quantitative ultrasound measures of liver parenchyma : prospective evaluation in healthy children and adults", AJR Am J Roentgenol, 214, pp.557~565 (2020)
650. Sawh MC, "Normal range for MR elastography measured liver stiffness in children without liver disease", J Magn Reson Imaging, 51, pp.919~927 (2020)
651. Trout AT, "Diagnostic performance of MR elastography for liver fibrosis in children and young adults with a spectrum of liver diseases", Radiology, 287, pp.824~832 (2018)
652. Xanthakos SA, "Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease", J Pediatr, 164, pp.186~188 (2014)
653. Schwimmer JB, "Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease", Hepatology, 66, pp.1474~1485 (2017)
654. Nielsen J, "Noninvasive prediction of advanced fibrosis in pediatric liver disease-discriminatory performance of 2D shear wave elastography, transient elastography and magnetic resonance elastography in comparison to histopathology", Diagnostics(Basel), 12, pp.2785~ (2022)

관련 논문AI추천